Since 20–40% of NMOSD cases are negative for AQP4 antibodies5 and treatment of NMOSD with some MS therapeutics can be harmful,3 additional biomarkers for distinguishing NMOSD from MS could aid diagnosis and treatment. This evidence concerns the gene AQP4 and myeloid sarcoma.